[Experimental aspergillosis in mice].
The experimentally induced aspergillosis of mice is discussed as a useful parameter for the screening of new antimycotics. There are important differences between this test model and aspergillus infections in humans. Mice must be infected intravenously with more than 10(6) spores of Aspergillus fumigatus to provoke multiple abscess formation in the kidneys which induces an acute, lethal course of infection. Intratracheal administration of 2 x 10(6) spores did not evoke any symptoms. The therapeutic efficacy of several antimycotics was examined; amphotericin B, 5-fluorocytosine and BAY h 4364--as the only imidazole-derivative--proved to be effective.
D000666:Amphotericin B / Q000627:therapeutic use; D000818:Animals; D000935:Antifungal Agents / Q000627:therapeutic use*; D001228:Aspergillosis / Q000188:drug therapy*; D001232:Aspergillus fumigatus; D004353:Drug Evaluation, Preclinical; D005437:Flucytosine / Q000627:therapeutic use; D005449:Fluorenes / Q000627:therapeutic use; D007093:Imidazoles / Q000627:therapeutic use; D051379:Mice
D000935:Antifungal Agents; D005449:Fluorenes; D007093:Imidazoles; D000666:Amphotericin B; D005437:Flucytosine
L'aspergillose expérimentale de la souris.